Corrigendum to “Abstract 066: Safety and Long Term Outcomes of Using Beta Blockers After Heart Transplantation”

2015 ◽  
Vol 21 (10) ◽  
pp. 856
2015 ◽  
Vol 21 (8) ◽  
pp. S37-S38 ◽  
Author(s):  
Amaninderapal S. Ghotra ◽  
Christopher Angus ◽  
John Price ◽  
Zeeshan Hussain ◽  
Kelly McCants ◽  
...  

Hypertension ◽  
2012 ◽  
Vol 60 (suppl_1) ◽  
Author(s):  
Avinash Murthy ◽  
Jaspreet Arora ◽  
Amar Shah ◽  
Hussain Khawaja ◽  
Mikhail Torosoff

Background: Effects of pulse pressure and benefits of blood pressure lowering with intravenous anti-hypertensive medications and beta-blockers in CVA patients have not been well investigated. Material and Methods: Demographic, clinical, and echocardiographic data were collected and long-term outcomes (55+/-21 months) were ascertained in 356 consecutive cerebro-vascular accident (CVA) patients. ANOVA, chi-square, Kaplan-Meier, and logistic regression tests were employed. Study was approved by the institutional IRB. Results: Widened pulse pressure on admission was significantly elevated in CVA patients who expired in the hospital or during the long-term follow-up (62+/-21mmHg for long-term survivors vs. 72+/-20mmHg for hospital deaths vs. 69+/-28 mmHg for long-term deaths, p=0.01). There was a trend towards increased hospital mortality (14% in long-term survivors vs. 25% in hospital deaths vs. 22% in long-term deaths, p=0.110) in CVA patients requiring IV anti-hypertensive therapy. Utilization of beta-blockers was lower in patients who suffered hospital death, but more likely in patients experiencing long-term death (42% use in hospital deaths vs. 48% in long-term survivors vs. vs. 66% in long-term deaths, p=0.003). Beta-blocker use was not predictive of hospital outcomes but was strongly predictive of adverse event long-term events (HR 2.1, 95%CI 1.3-3.4, p=0.002). When adjusted for demographic parameters and co-morbidities in multivariate analysis, pulse pressure and IV anti-hypertensive therapy were not predictive of short or long-term outcomes, while beta-blocker treatment was associated with reduced hospital (0.3, 95%CI 0.1-0.9, p=0.029) but not long-term mortality. Conclusions: Widened pulse pressure and need for IV anti-hypertensive therapy are not predictive of adverse short- or long-term outcomes when demographics and co-morbidities are accounted for. Effects of beta-blocker therapy on outcomes in CVA patients are complex. Wider beta-blocker use in acute CVA may be associated with better hospital outcomes, while increased long term mortality with beta-blocker therapy may be indicative of poor cardiovascular health leading to adverse outcomes


2013 ◽  
Vol 34 (suppl 1) ◽  
pp. P5099-P5099
Author(s):  
S. Cohen ◽  
C. Aubailly ◽  
N. Danchin ◽  
S. Varnous ◽  
A. Pavie

2008 ◽  
Vol 27 (8) ◽  
pp. 830-834 ◽  
Author(s):  
Daniel Marelli ◽  
Jon Kobashigawa ◽  
Michele A. Hamilton ◽  
Jaime D. Moriguchi ◽  
Reza Kermani ◽  
...  

Heart ◽  
2021 ◽  
pp. heartjnl-2020-318028
Author(s):  
Christopher Lau ◽  
Sarah Chiu ◽  
Rohith Nayak ◽  
Bryan Lin ◽  
Ming-Sum Lee

ObjectiveThe goal of this study is to evaluate the long-term outcomes of patients with takotsubo syndrome and assess factors associated with death or recurrence.MethodsThis is a retrospective population-based cohort study of consecutive patients who presented to an integrated health system in Southern California with takotsubo syndrome between 2006 and 2016. Medical records were manually reviewed to confirm diagnosis and to identify predisposing factors, medication treatment and long-term outcomes. Factors associated with death or recurrent takotsubo syndrome were tested using Cox regression models.ResultsBetween 2006 and 2016, there were 519 patients with a confirmed diagnosis of takotsubo syndrome. Patients were followed for 5.2 years (IQR 3.0–7.2). During the follow-up period, 39 (7.5%) had recurrent takotsubo syndrome and 84 (16.2%) died. In multivariate modelling, factors associated with higher risk of recurrence or death were age (HR 1.56 per 10-year increase, 95% CI 1.29 to 1.87), male sex (HR 2.52, 95% CI 1.38 to 4.60), diabetes (HR 1.6, 95% CI 1.06 to 2.43), pulmonary disease (HR 2.0, 95% CI 1.37 to 2.91) and chronic kidney disease (HR 1.58, 95% CI 1.01 to 2.47). Treatment with beta-blockers were associated with lower risk of recurrence or death (HR 0.46, 95% CI 0.29 to 0.72). No association was observed between treatment with ACE inhibitors or angiotensin-receptor blockers and recurrence or death (HR 0.92, 95% CI 0.59 to 1.42).ConclusionsRecurrent takotsubo syndrome occurred in a minor subset of patients. Treatment with beta-blocker was associated with higher event-free survival.


2018 ◽  
Vol 37 (4) ◽  
pp. S324
Author(s):  
Y. Peled ◽  
Y. Kassif ◽  
E. Raichlin ◽  
A. Kogan ◽  
Y. Har-Zahav ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document